Pembrolizumab – March 2022

• Brand names:
  • Keytruda®
• Pharmaceutical Company:
  • Merck Sharp & Dohme (Australia) Pty Ltd
• Condition/Indication: Endometrial cancer
• Meeting Date: March 2022
• Public Summary Document (PSD) March 2022 March 2023 PBAC Meetings - (PDF 1.1MB)
• Public Summary Document (PSD) March 2022 March 2023 PBAC Meetings - (Word 796KB)

Related Public Summary Documents

Pembrolizumab – March 2023